APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurokinin Receptor Antagonists API

Compare research editions
View pricing & licenses

Selected research

Industry Research

Neurokinin Receptor Antagonists API Industry Research Report 2026

28 December 2025151 pages

Choose your research edition.

Industry ResearchNeurokinin Receptor Antagonists API Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurokinin Receptor Antagonists API Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Neurokinin Receptor Antagonists API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurokinin Receptor Antagonists API Market Outlook and Growth Opportunities 2026211 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurokinin Receptor Antagonists API Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

The global Neurokinin Receptor Antagonists API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Neurokinin Receptor Antagonists API is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Neurokinin Receptor Antagonists API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Neurokinin Receptor Antagonists API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Neurokinin Receptor Antagonists API include Zhejiang Tiantai Pharmaceutical, Humanwell Pharmaceutical, Viwit, Sichuan Qingmu Pharmaceutical, Kelun Pharmaceutical, Shandong New Time Pharmaceutical, Shandong Anxin Pharmaceutical, Qilu Pharmaceutical and Luoxin Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Neurokinin Receptor Antagonists API market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Neurokinin Receptor Antagonists API Market by Company

Zhejiang Tiantai Pharmaceutical

Humanwell Pharmaceutical

Viwit

Sichuan Qingmu Pharmaceutical

Kelun Pharmaceutical

Shandong New Time Pharmaceutical

Shandong Anxin Pharmaceutical

Qilu Pharmaceutical

Luoxin Pharmaceuticals

Lianyungang Runzhong Pharmaceutical

Wisdom Pharmaceutical

Hansoh Pharma

United Pharma

Hangzhou Jiuyuan Gene Engineering

Beijing Sjar Technology Development

Zydus Animal Health And Investments

Taizhou Crene Biotechnology

Solara Active Pharma Sciences

Procos

Piramal Pharma

Optimus Pharma

Murli Krishna Pharma

MSN Laboratories

Jubilant Pharmova

Helsinn Advanced Synthesis

Glenmark Life Sciences

Dr. Reddy's Laboratories

Clearsynth Labs

Camus Pharma

Andenex

Neurokinin Receptor Antagonists API Segment by Type

Aprepitant

Fezolinetant

Fosaprepitant

Rolapitant

Maropitant

Netupitant

Neurokinin Receptor Antagonists API Segment by Application

Injections

Tablets

Oral Suspension

Capsules

Other

Neurokinin Receptor Antagonists API Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurokinin Receptor Antagonists API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurokinin Receptor Antagonists API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurokinin Receptor Antagonists API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Neurokinin Receptor Antagonists API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Neurokinin Receptor Antagonists API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Neurokinin Receptor Antagonists API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Neurokinin Receptor Antagonists API Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Neurokinin Receptor Antagonists API Sales (Tons) of Manufacturers (2021-2026) Table 7. Global Neurokinin Receptor Antagonists API Sales Market Share by Manufacturers (2021-2026) Table 8. Global Neurokinin Receptor Antagonists API Revenue of Manufacturers (2021-2026) Table 9. Global Neurokinin Receptor Antagonists API Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Neurokinin Receptor Antagonists API Average Price (US$/Kg) of Manufacturers (2021-2026) Table 11. Global Neurokinin Receptor Antagonists API Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Neurokinin Receptor Antagonists API, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Neurokinin Receptor Antagonists API, Product Type & Application Table 14. Global Neurokinin Receptor Antagonists API Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Neurokinin Receptor Antagonists API by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Zhejiang Tiantai Pharmaceutical Company Information Table 19. Zhejiang Tiantai Pharmaceutical Business Overview Table 20. Zhejiang Tiantai Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 21. Zhejiang Tiantai Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 22. Zhejiang Tiantai Pharmaceutical Recent Developments Table 23. Humanwell Pharmaceutical Company Information Table 24. Humanwell Pharmaceutical Business Overview Table 25. Humanwell Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 26. Humanwell Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 27. Humanwell Pharmaceutical Recent Developments Table 28. Viwit Company Information Table 29. Viwit Business Overview Table 30. Viwit Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 31. Viwit Neurokinin Receptor Antagonists API Product Portfolio Table 32. Viwit Recent Developments Table 33. Sichuan Qingmu Pharmaceutical Company Information Table 34. Sichuan Qingmu Pharmaceutical Business Overview Table 35. Sichuan Qingmu Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 36. Sichuan Qingmu Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 37. Sichuan Qingmu Pharmaceutical Recent Developments Table 38. Kelun Pharmaceutical Company Information Table 39. Kelun Pharmaceutical Business Overview Table 40. Kelun Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 41. Kelun Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 42. Kelun Pharmaceutical Recent Developments Table 43. Shandong New Time Pharmaceutical Company Information Table 44. Shandong New Time Pharmaceutical Business Overview Table 45. Shandong New Time Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 46. Shandong New Time Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 47. Shandong New Time Pharmaceutical Recent Developments Table 48. Shandong Anxin Pharmaceutical Company Information Table 49. Shandong Anxin Pharmaceutical Business Overview Table 50. Shandong Anxin Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 51. Shandong Anxin Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 52. Shandong Anxin Pharmaceutical Recent Developments Table 53. Qilu Pharmaceutical Company Information Table 54. Qilu Pharmaceutical Business Overview Table 55. Qilu Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 56. Qilu Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 57. Qilu Pharmaceutical Recent Developments Table 58. Luoxin Pharmaceuticals Company Information Table 59. Luoxin Pharmaceuticals Business Overview Table 60. Luoxin Pharmaceuticals Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 61. Luoxin Pharmaceuticals Neurokinin Receptor Antagonists API Product Portfolio Table 62. Luoxin Pharmaceuticals Recent Developments Table 63. Lianyungang Runzhong Pharmaceutical Company Information Table 64. Lianyungang Runzhong Pharmaceutical Business Overview Table 65. Lianyungang Runzhong Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 66. Lianyungang Runzhong Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 67. Lianyungang Runzhong Pharmaceutical Recent Developments Table 68. Wisdom Pharmaceutical Company Information Table 69. Wisdom Pharmaceutical Business Overview Table 70. Wisdom Pharmaceutical Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 71. Wisdom Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio Table 72. Wisdom Pharmaceutical Recent Developments Table 73. Hansoh Pharma Company Information Table 74. Hansoh Pharma Business Overview Table 75. Hansoh Pharma Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 76. Hansoh Pharma Neurokinin Receptor Antagonists API Product Portfolio Table 77. Hansoh Pharma Recent Developments Table 78. United Pharma Company Information Table 79. United Pharma Business Overview Table 80. United Pharma Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 81. United Pharma Neurokinin Receptor Antagonists API Product Portfolio Table 82. United Pharma Recent Developments Table 83. Hangzhou Jiuyuan Gene Engineering Company Information Table 84. Hangzhou Jiuyuan Gene Engineering Business Overview Table 85. Hangzhou Jiuyuan Gene Engineering Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 86. Hangzhou Jiuyuan Gene Engineering Neurokinin Receptor Antagonists API Product Portfolio Table 87. Hangzhou Jiuyuan Gene Engineering Recent Developments Table 88. Beijing Sjar Technology Development Company Information Table 89. Beijing Sjar Technology Development Business Overview Table 90. Beijing Sjar Technology Development Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 91. Beijing Sjar Technology Development Neurokinin Receptor Antagonists API Product Portfolio Table 92. Beijing Sjar Technology Development Recent Developments Table 93. Zydus Animal Health And Investments Company Information Table 94. Zydus Animal Health And Investments Business Overview Table 95. Zydus Animal Health And Investments Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 96. Zydus Animal Health And Investments Neurokinin Receptor Antagonists API Product Portfolio Table 97. Zydus Animal Health And Investments Recent Developments Table 98. Taizhou Crene Biotechnology Company Information Table 99. Taizhou Crene Biotechnology Business Overview Table 100. Taizhou Crene Biotechnology Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 101. Taizhou Crene Biotechnology Neurokinin Receptor Antagonists API Product Portfolio Table 102. Taizhou Crene Biotechnology Recent Developments Table 103. Solara Active Pharma Sciences Company Information Table 104. Solara Active Pharma Sciences Business Overview Table 105. Solara Active Pharma Sciences Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 106. Solara Active Pharma Sciences Neurokinin Receptor Antagonists API Product Portfolio Table 107. Solara Active Pharma Sciences Recent Developments Table 108. Procos Company Information Table 109. Procos Business Overview Table 110. Procos Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 111. Procos Neurokinin Receptor Antagonists API Product Portfolio Table 112. Procos Recent Developments Table 113. Piramal Pharma Company Information Table 114. Piramal Pharma Business Overview Table 115. Piramal Pharma Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 116. Piramal Pharma Neurokinin Receptor Antagonists API Product Portfolio Table 117. Piramal Pharma Recent Developments Table 118. Optimus Pharma Company Information Table 119. Optimus Pharma Business Overview Table 120. Optimus Pharma Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 121. Optimus Pharma Neurokinin Receptor Antagonists API Product Portfolio Table 122. Optimus Pharma Recent Developments Table 123. Murli Krishna Pharma Company Information Table 124. Murli Krishna Pharma Business Overview Table 125. Murli Krishna Pharma Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 126. Murli Krishna Pharma Neurokinin Receptor Antagonists API Product Portfolio Table 127. Murli Krishna Pharma Recent Developments Table 128. MSN Laboratories Company Information Table 129. MSN Laboratories Business Overview Table 130. MSN Laboratories Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 131. MSN Laboratories Neurokinin Receptor Antagonists API Product Portfolio Table 132. MSN Laboratories Recent Developments Table 133. Jubilant Pharmova Company Information Table 134. Jubilant Pharmova Business Overview Table 135. Jubilant Pharmova Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 136. Jubilant Pharmova Neurokinin Receptor Antagonists API Product Portfolio Table 137. Jubilant Pharmova Recent Developments Table 138. Helsinn Advanced Synthesis Company Information Table 139. Helsinn Advanced Synthesis Business Overview Table 140. Helsinn Advanced Synthesis Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 141. Helsinn Advanced Synthesis Neurokinin Receptor Antagonists API Product Portfolio Table 142. Helsinn Advanced Synthesis Recent Developments Table 143. Glenmark Life Sciences Company Information Table 144. Glenmark Life Sciences Business Overview Table 145. Glenmark Life Sciences Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 146. Glenmark Life Sciences Neurokinin Receptor Antagonists API Product Portfolio Table 147. Glenmark Life Sciences Recent Developments Table 148. Dr. Reddy's Laboratories Company Information Table 149. Dr. Reddy's Laboratories Business Overview Table 150. Dr. Reddy's Laboratories Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 151. Dr. Reddy's Laboratories Neurokinin Receptor Antagonists API Product Portfolio Table 152. Dr. Reddy's Laboratories Recent Developments Table 153. Clearsynth Labs Company Information Table 154. Clearsynth Labs Business Overview Table 155. Clearsynth Labs Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 156. Clearsynth Labs Neurokinin Receptor Antagonists API Product Portfolio Table 157. Clearsynth Labs Recent Developments Table 158. Camus Pharma Company Information Table 159. Camus Pharma Business Overview Table 160. Camus Pharma Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 161. Camus Pharma Neurokinin Receptor Antagonists API Product Portfolio Table 162. Camus Pharma Recent Developments Table 163. Andenex Company Information Table 164. Andenex Business Overview Table 165. Andenex Neurokinin Receptor Antagonists API Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 166. Andenex Neurokinin Receptor Antagonists API Product Portfolio Table 167. Andenex Recent Developments Table 168. Global Neurokinin Receptor Antagonists API Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 169. Global Neurokinin Receptor Antagonists API Sales by Region (2021-2026) & (Tons) Table 170. Global Neurokinin Receptor Antagonists API Sales Market Share by Region (2021-2026) Table 171. Global Neurokinin Receptor Antagonists API Sales by Region (2027-2032) & (Tons) Table 172. Global Neurokinin Receptor Antagonists API Sales Market Share by Region (2027-2032) Table 173. Global Neurokinin Receptor Antagonists API Revenue by Region (2021-2026) & (US$ Million) Table 174. Global Neurokinin Receptor Antagonists API Revenue Market Share by Region (2021-2026) Table 175. Global Neurokinin Receptor Antagonists API Revenue by Region (2027-2032) & (US$ Million) Table 176. Global Neurokinin Receptor Antagonists API Revenue Market Share by Region (2027-2032) Table 177. North America Neurokinin Receptor Antagonists API Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 178. North America Neurokinin Receptor Antagonists API Sales by Country (2021-2026) & (Tons) Table 179. North America Neurokinin Receptor Antagonists API Sales by Country (2027-2032) & (Tons) Table 180. North America Neurokinin Receptor Antagonists API Revenue by Country (2021-2026) & (US$ Million) Table 181. North America Neurokinin Receptor Antagonists API Revenue by Country (2027-2032) & (US$ Million) Table 182. Europe Neurokinin Receptor Antagonists API Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 183. Europe Neurokinin Receptor Antagonists API Sales by Country (2021-2026) & (Tons) Table 184. Europe Neurokinin Receptor Antagonists API Sales by Country (2027-2032) & (Tons) Table 185. Europe Neurokinin Receptor Antagonists API Revenue by Country (2021-2026) & (US$ Million) Table 186. Europe Neurokinin Receptor Antagonists API Revenue by Country (2027-2032) & (US$ Million) Table 187. Asia Pacific Neurokinin Receptor Antagonists API Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 188. Asia Pacific Neurokinin Receptor Antagonists API Sales by Country (2021-2026) & (Tons) Table 189. Asia Pacific Neurokinin Receptor Antagonists API Sales by Country (2027-2032) & (Tons) Table 190. Asia Pacific Neurokinin Receptor Antagonists API Revenue by Country (2021-2026) & (US$ Million) Table 191. Asia Pacific Neurokinin Receptor Antagonists API Revenue by Country (2027-2032) & (US$ Million) Table 192. South America Neurokinin Receptor Antagonists API Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 193. South America Neurokinin Receptor Antagonists API Sales by Country (2021-2026) & (Tons) Table 194. South America Neurokinin Receptor Antagonists API Sales by Country (2027-2032) & (Tons) Table 195. South America Neurokinin Receptor Antagonists API Revenue by Country (2021-2026) & (US$ Million) Table 196. South America Neurokinin Receptor Antagonists API Revenue by Country (2027-2032) & (US$ Million) Table 197. Middle East and Africa Neurokinin Receptor Antagonists API Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 198. Middle East and Africa Neurokinin Receptor Antagonists API Sales by Country (2021-2026) & (Tons) Table 199. Middle East and Africa Neurokinin Receptor Antagonists API Sales by Country (2027-2032) & (Tons) Table 200. Middle East and Africa Neurokinin Receptor Antagonists API Revenue by Country (2021-2026) & (US$ Million) Table 201. Middle East and Africa Neurokinin Receptor Antagonists API Revenue by Country (2027-2032) & (US$ Million) Table 202. Global Neurokinin Receptor Antagonists API Sales by Type (2021-2026) & (Tons) Table 203. Global Neurokinin Receptor Antagonists API Sales by Type (2027-2032) & (Tons) Table 204. Global Neurokinin Receptor Antagonists API Sales Market Share by Type (2021-2026) Table 205. Global Neurokinin Receptor Antagonists API Sales Market Share by Type (2027-2032) Table 206. Global Neurokinin Receptor Antagonists API Revenue by Type (2021-2026) & (US$ Million) Table 207. Global Neurokinin Receptor Antagonists API Revenue by Type (2027-2032) & (US$ Million) Table 208. Global Neurokinin Receptor Antagonists API Revenue Market Share by Type (2021-2026) Table 209. Global Neurokinin Receptor Antagonists API Revenue Market Share by Type (2027-2032) Table 210. Global Neurokinin Receptor Antagonists API Price by Type (2021-2026) & (US$/Kg) Table 211. Global Neurokinin Receptor Antagonists API Price by Type (2027-2032) & (US$/Kg) Table 212. Global Neurokinin Receptor Antagonists API Sales by Application (2021-2026) & (Tons) Table 213. Global Neurokinin Receptor Antagonists API Sales by Application (2027-2032) & (Tons) Table 214. Global Neurokinin Receptor Antagonists API Sales Market Share by Application (2021-2026) Table 215. Global Neurokinin Receptor Antagonists API Sales Market Share by Application (2027-2032) Table 216. Global Neurokinin Receptor Antagonists API Revenue by Application (2021-2026) & (US$ Million) Table 217. Global Neurokinin Receptor Antagonists API Revenue by Application (2027-2032) & (US$ Million) Table 218. Global Neurokinin Receptor Antagonists API Revenue Market Share by Application (2021-2026) Table 219. Global Neurokinin Receptor Antagonists API Revenue Market Share by Application (2027-2032) Table 220. Global Neurokinin Receptor Antagonists API Price by Application (2021-2026) & (US$/Kg) Table 221. Global Neurokinin Receptor Antagonists API Price by Application (2027-2032) & (US$/Kg) Table 222. Key Raw Materials Table 223. Raw Materials Key Suppliers Table 224. Neurokinin Receptor Antagonists API Distributors List Table 225. Neurokinin Receptor Antagonists API Customers List Table 226. Neurokinin Receptor Antagonists API Industry Trends Table 227. Neurokinin Receptor Antagonists API Industry Drivers Table 228. Neurokinin Receptor Antagonists API Industry Restraints Table 229. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Neurokinin Receptor Antagonists API Product Image Figure 5. Global Neurokinin Receptor Antagonists API Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Neurokinin Receptor Antagonists API Market Size (2021-2032) & (US$ Million) Figure 7. Global Neurokinin Receptor Antagonists API Sales (2021-2032) & (Tons) Figure 8. Global Neurokinin Receptor Antagonists API Average Price (US$/Kg) & (2021-2032) Figure 9. Aprepitant Product Image Figure 10. Fezolinetant Product Image Figure 11. Fosaprepitant Product Image Figure 12. Rolapitant Product Image Figure 13. Maropitant Product Image Figure 14. Netupitant Product Image Figure 15. Injections Product Image Figure 16. Tablets Product Image Figure 17. Oral Suspension Product Image Figure 18. Capsules Product Image Figure 19. Other Product Image Figure 20. Global Neurokinin Receptor Antagonists API Revenue Share by Manufacturers in 2025 Figure 21. Global Manufacturers of Neurokinin Receptor Antagonists API, Manufacturing Sites & Headquarters Figure 22. Global Top 5 and 10 Neurokinin Receptor Antagonists API Players Market Share by Revenue in 2025 Figure 23. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 24. Global Neurokinin Receptor Antagonists API Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 25. Global Neurokinin Receptor Antagonists API Sales by Region in 2025 Figure 26. Global Neurokinin Receptor Antagonists API Revenue by Region in 2025 Figure 27. North America Neurokinin Receptor Antagonists API Market Size by Country in 2025 Figure 28. North America Neurokinin Receptor Antagonists API Sales Market Share by Country (2021-2032) Figure 29. North America Neurokinin Receptor Antagonists API Revenue Market Share by Country (2021-2032) Figure 30. United States Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Canada Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Mexico Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Europe Neurokinin Receptor Antagonists API Market Size by Country in 2025 Figure 34. Europe Neurokinin Receptor Antagonists API Sales Market Share by Country (2021-2032) Figure 35. Europe Neurokinin Receptor Antagonists API Revenue Market Share by Country (2021-2032) Figure 36. Germany Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. France Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. U.K. Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Italy Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Russia Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Spain Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Netherlands Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Switzerland Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Sweden Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Poland Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Asia Pacific Neurokinin Receptor Antagonists API Market Size by Country in 2025 Figure 47. Asia Pacific Neurokinin Receptor Antagonists API Sales Market Share by Country (2021-2032) Figure 48. Asia Pacific Neurokinin Receptor Antagonists API Revenue Market Share by Country (2021-2032) Figure 49. China Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Japan Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South Korea Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. India Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Australia Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Taiwan Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Southeast Asia Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. South America Neurokinin Receptor Antagonists API Market Size by Country in 2025 Figure 58. South America Neurokinin Receptor Antagonists API Sales Market Share by Country (2021-2032) Figure 59. South America Neurokinin Receptor Antagonists API Revenue Market Share by Country (2021-2032) Figure 60. Brazil Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Argentina Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Chile Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Middle East and Africa Neurokinin Receptor Antagonists API Market Size by Country in 2025 Figure 64. Middle East and Africa Neurokinin Receptor Antagonists API Sales Market Share by Country (2021-2032) Figure 65. Middle East and Africa Neurokinin Receptor Antagonists API Revenue Market Share by Country (2021-2032) Figure 66. Egypt Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. South Africa Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Israel Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Türkiye Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. GCC Countries Neurokinin Receptor Antagonists API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 71. Global Neurokinin Receptor Antagonists API Sales Market Share by Type (2021-2032) Figure 72. Global Neurokinin Receptor Antagonists API Revenue Market Share by Type (2021-2032) Figure 73. Global Neurokinin Receptor Antagonists API Price (US$/Kg) by Type (2021-2032) Figure 74. Global Neurokinin Receptor Antagonists API Sales Market Share by Application (2021-2032) Figure 75. Global Neurokinin Receptor Antagonists API Revenue Market Share by Application (2021-2032) Figure 76. Global Neurokinin Receptor Antagonists API Price (US$/Kg) by Application (2021-2032) Figure 77. Neurokinin Receptor Antagonists API Value Chain Figure 78. Neurokinin Receptor Antagonists API Production Mode & Process Figure 79. Direct Comparison with Distribution Share Figure 80. Distributors Profiles Figure 81. Neurokinin Receptor Antagonists API Industry Opportunities and Challenges

Scope & coverage.

Types
  • Aprepitant
  • Fezolinetant
  • Fosaprepitant
  • Rolapitant
  • Maropitant
  • Netupitant
Applications
  • Injections
  • Tablets
  • Oral Suspension
  • Capsules
  • Other
Companies covered
  • Zhejiang Tiantai Pharmaceutical
  • Humanwell Pharmaceutical
  • Viwit
  • Sichuan Qingmu Pharmaceutical
  • Kelun Pharmaceutical
  • Shandong New Time Pharmaceutical
  • Shandong Anxin Pharmaceutical
  • Qilu Pharmaceutical
  • Luoxin Pharmaceuticals
  • Lianyungang Runzhong Pharmaceutical
  • Wisdom Pharmaceutical
  • Hansoh Pharma
  • United Pharma
  • Hangzhou Jiuyuan Gene Engineering
  • Beijing Sjar Technology Development
  • Zydus Animal Health And Investments
  • Taizhou Crene Biotechnology
  • Solara Active Pharma Sciences
  • Procos
  • Piramal Pharma
  • Optimus Pharma
  • Murli Krishna Pharma
  • MSN Laboratories
  • Jubilant Pharmova
  • Helsinn Advanced Synthesis
  • Glenmark Life Sciences
  • Dr. Reddy's Laboratories
  • Clearsynth Labs
  • Camus Pharma
  • Andenex

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Neurokinin Receptor Antagonists API Market Size (2021-2032)
  4. 2.2.2 Global Neurokinin Receptor Antagonists API Sales (2021-2032)
  5. 2.2.3 Global Neurokinin Receptor Antagonists API Market Average Price (2021-2032)
  6. 2.3 Neurokinin Receptor Antagonists API by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Aprepitant
  9. 2.3.3 Fezolinetant
  10. 2.3.4 Fosaprepitant
  11. 2.3.5 Rolapitant
  12. 2.3.6 Maropitant
  13. 2.3.7 Netupitant
  14. 2.4 Neurokinin Receptor Antagonists API by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Injections
  17. 2.4.3 Tablets
  18. 2.4.4 Oral Suspension
  19. 2.4.5 Capsules
  20. 2.4.6 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Neurokinin Receptor Antagonists API Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Neurokinin Receptor Antagonists API Sales (Tons) of Manufacturers (2021-2026)
  3. 3.3 Global Neurokinin Receptor Antagonists API Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Neurokinin Receptor Antagonists API Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Neurokinin Receptor Antagonists API Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Neurokinin Receptor Antagonists API, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Neurokinin Receptor Antagonists API, Product Type & Application
  8. 3.8 Global Manufacturers of Neurokinin Receptor Antagonists API, Established Date
  9. 3.9 Global Neurokinin Receptor Antagonists API Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Zhejiang Tiantai Pharmaceutical
  2. 4.1.1 Zhejiang Tiantai Pharmaceutical Company Information
  3. 4.1.2 Zhejiang Tiantai Pharmaceutical Business Overview
  4. 4.1.3 Zhejiang Tiantai Pharmaceutical Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Zhejiang Tiantai Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  6. 4.1.5 Zhejiang Tiantai Pharmaceutical Recent Developments
  7. 4.2 Humanwell Pharmaceutical
  8. 4.2.1 Humanwell Pharmaceutical Company Information
  9. 4.2.2 Humanwell Pharmaceutical Business Overview
  10. 4.2.3 Humanwell Pharmaceutical Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Humanwell Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  12. 4.2.5 Humanwell Pharmaceutical Recent Developments
  13. 4.3 Viwit
  14. 4.3.1 Viwit Company Information
  15. 4.3.2 Viwit Business Overview
  16. 4.3.3 Viwit Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Viwit Neurokinin Receptor Antagonists API Product Portfolio
  18. 4.3.5 Viwit Recent Developments
  19. 4.4 Sichuan Qingmu Pharmaceutical
  20. 4.4.1 Sichuan Qingmu Pharmaceutical Company Information
  21. 4.4.2 Sichuan Qingmu Pharmaceutical Business Overview
  22. 4.4.3 Sichuan Qingmu Pharmaceutical Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Sichuan Qingmu Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  24. 4.4.5 Sichuan Qingmu Pharmaceutical Recent Developments
  25. 4.5 Kelun Pharmaceutical
  26. 4.5.1 Kelun Pharmaceutical Company Information
  27. 4.5.2 Kelun Pharmaceutical Business Overview
  28. 4.5.3 Kelun Pharmaceutical Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Kelun Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  30. 4.5.5 Kelun Pharmaceutical Recent Developments
  31. 4.6 Shandong New Time Pharmaceutical
  32. 4.6.1 Shandong New Time Pharmaceutical Company Information
  33. 4.6.2 Shandong New Time Pharmaceutical Business Overview
  34. 4.6.3 Shandong New Time Pharmaceutical Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Shandong New Time Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  36. 4.6.5 Shandong New Time Pharmaceutical Recent Developments
  37. 4.7 Shandong Anxin Pharmaceutical
  38. 4.7.1 Shandong Anxin Pharmaceutical Company Information
  39. 4.7.2 Shandong Anxin Pharmaceutical Business Overview
  40. 4.7.3 Shandong Anxin Pharmaceutical Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Shandong Anxin Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  42. 4.7.5 Shandong Anxin Pharmaceutical Recent Developments
  43. 4.8 Qilu Pharmaceutical
  44. 4.8.1 Qilu Pharmaceutical Company Information
  45. 4.8.2 Qilu Pharmaceutical Business Overview
  46. 4.8.3 Qilu Pharmaceutical Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Qilu Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  48. 4.8.5 Qilu Pharmaceutical Recent Developments
  49. 4.9 Luoxin Pharmaceuticals
  50. 4.9.1 Luoxin Pharmaceuticals Company Information
  51. 4.9.2 Luoxin Pharmaceuticals Business Overview
  52. 4.9.3 Luoxin Pharmaceuticals Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Luoxin Pharmaceuticals Neurokinin Receptor Antagonists API Product Portfolio
  54. 4.9.5 Luoxin Pharmaceuticals Recent Developments
  55. 4.10 Lianyungang Runzhong Pharmaceutical
  56. 4.10.1 Lianyungang Runzhong Pharmaceutical Company Information
  57. 4.10.2 Lianyungang Runzhong Pharmaceutical Business Overview
  58. 4.10.3 Lianyungang Runzhong Pharmaceutical Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Lianyungang Runzhong Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  60. 4.10.5 Lianyungang Runzhong Pharmaceutical Recent Developments
  61. 4.11 Wisdom Pharmaceutical
  62. 4.11.1 Wisdom Pharmaceutical Company Information
  63. 4.11.2 Wisdom Pharmaceutical Business Overview
  64. 4.11.3 Wisdom Pharmaceutical Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Wisdom Pharmaceutical Neurokinin Receptor Antagonists API Product Portfolio
  66. 4.11.5 Wisdom Pharmaceutical Recent Developments
  67. 4.12 Hansoh Pharma
  68. 4.12.1 Hansoh Pharma Company Information
  69. 4.12.2 Hansoh Pharma Business Overview
  70. 4.12.3 Hansoh Pharma Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Hansoh Pharma Neurokinin Receptor Antagonists API Product Portfolio
  72. 4.12.5 Hansoh Pharma Recent Developments
  73. 4.13 United Pharma
  74. 4.13.1 United Pharma Company Information
  75. 4.13.2 United Pharma Business Overview
  76. 4.13.3 United Pharma Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 United Pharma Neurokinin Receptor Antagonists API Product Portfolio
  78. 4.13.5 United Pharma Recent Developments
  79. 4.14 Hangzhou Jiuyuan Gene Engineering
  80. 4.14.1 Hangzhou Jiuyuan Gene Engineering Company Information
  81. 4.14.2 Hangzhou Jiuyuan Gene Engineering Business Overview
  82. 4.14.3 Hangzhou Jiuyuan Gene Engineering Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Hangzhou Jiuyuan Gene Engineering Neurokinin Receptor Antagonists API Product Portfolio
  84. 4.14.5 Hangzhou Jiuyuan Gene Engineering Recent Developments
  85. 4.15 Beijing Sjar Technology Development
  86. 4.15.1 Beijing Sjar Technology Development Company Information
  87. 4.15.2 Beijing Sjar Technology Development Business Overview
  88. 4.15.3 Beijing Sjar Technology Development Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Beijing Sjar Technology Development Neurokinin Receptor Antagonists API Product Portfolio
  90. 4.15.5 Beijing Sjar Technology Development Recent Developments
  91. 4.16 Zydus Animal Health And Investments
  92. 4.16.1 Zydus Animal Health And Investments Company Information
  93. 4.16.2 Zydus Animal Health And Investments Business Overview
  94. 4.16.3 Zydus Animal Health And Investments Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Zydus Animal Health And Investments Neurokinin Receptor Antagonists API Product Portfolio
  96. 4.16.5 Zydus Animal Health And Investments Recent Developments
  97. 4.17 Taizhou Crene Biotechnology
  98. 4.17.1 Taizhou Crene Biotechnology Company Information
  99. 4.17.2 Taizhou Crene Biotechnology Business Overview
  100. 4.17.3 Taizhou Crene Biotechnology Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Taizhou Crene Biotechnology Neurokinin Receptor Antagonists API Product Portfolio
  102. 4.17.5 Taizhou Crene Biotechnology Recent Developments
  103. 4.18 Solara Active Pharma Sciences
  104. 4.18.1 Solara Active Pharma Sciences Company Information
  105. 4.18.2 Solara Active Pharma Sciences Business Overview
  106. 4.18.3 Solara Active Pharma Sciences Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Solara Active Pharma Sciences Neurokinin Receptor Antagonists API Product Portfolio
  108. 4.18.5 Solara Active Pharma Sciences Recent Developments
  109. 4.19 Procos
  110. 4.19.1 Procos Company Information
  111. 4.19.2 Procos Business Overview
  112. 4.19.3 Procos Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Procos Neurokinin Receptor Antagonists API Product Portfolio
  114. 4.19.5 Procos Recent Developments
  115. 4.20 Piramal Pharma
  116. 4.20.1 Piramal Pharma Company Information
  117. 4.20.2 Piramal Pharma Business Overview
  118. 4.20.3 Piramal Pharma Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Piramal Pharma Neurokinin Receptor Antagonists API Product Portfolio
  120. 4.20.5 Piramal Pharma Recent Developments
  121. 4.21 Optimus Pharma
  122. 4.21.1 Optimus Pharma Company Information
  123. 4.21.2 Optimus Pharma Business Overview
  124. 4.21.3 Optimus Pharma Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Optimus Pharma Neurokinin Receptor Antagonists API Product Portfolio
  126. 4.21.5 Optimus Pharma Recent Developments
  127. 4.22 Murli Krishna Pharma
  128. 4.22.1 Murli Krishna Pharma Company Information
  129. 4.22.2 Murli Krishna Pharma Business Overview
  130. 4.22.3 Murli Krishna Pharma Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Murli Krishna Pharma Neurokinin Receptor Antagonists API Product Portfolio
  132. 4.22.5 Murli Krishna Pharma Recent Developments
  133. 4.23 MSN Laboratories
  134. 4.23.1 MSN Laboratories Company Information
  135. 4.23.2 MSN Laboratories Business Overview
  136. 4.23.3 MSN Laboratories Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 MSN Laboratories Neurokinin Receptor Antagonists API Product Portfolio
  138. 4.23.5 MSN Laboratories Recent Developments
  139. 4.24 Jubilant Pharmova
  140. 4.24.1 Jubilant Pharmova Company Information
  141. 4.24.2 Jubilant Pharmova Business Overview
  142. 4.24.3 Jubilant Pharmova Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Jubilant Pharmova Neurokinin Receptor Antagonists API Product Portfolio
  144. 4.24.5 Jubilant Pharmova Recent Developments
  145. 4.25 Helsinn Advanced Synthesis
  146. 4.25.1 Helsinn Advanced Synthesis Company Information
  147. 4.25.2 Helsinn Advanced Synthesis Business Overview
  148. 4.25.3 Helsinn Advanced Synthesis Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  149. 4.25.4 Helsinn Advanced Synthesis Neurokinin Receptor Antagonists API Product Portfolio
  150. 4.25.5 Helsinn Advanced Synthesis Recent Developments
  151. 4.26 Glenmark Life Sciences
  152. 4.26.1 Glenmark Life Sciences Company Information
  153. 4.26.2 Glenmark Life Sciences Business Overview
  154. 4.26.3 Glenmark Life Sciences Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  155. 4.26.4 Glenmark Life Sciences Neurokinin Receptor Antagonists API Product Portfolio
  156. 4.26.5 Glenmark Life Sciences Recent Developments
  157. 4.27 Dr. Reddy's Laboratories
  158. 4.27.1 Dr. Reddy's Laboratories Company Information
  159. 4.27.2 Dr. Reddy's Laboratories Business Overview
  160. 4.27.3 Dr. Reddy's Laboratories Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  161. 4.27.4 Dr. Reddy's Laboratories Neurokinin Receptor Antagonists API Product Portfolio
  162. 4.27.5 Dr. Reddy's Laboratories Recent Developments
  163. 4.28 Clearsynth Labs
  164. 4.28.1 Clearsynth Labs Company Information
  165. 4.28.2 Clearsynth Labs Business Overview
  166. 4.28.3 Clearsynth Labs Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  167. 4.28.4 Clearsynth Labs Neurokinin Receptor Antagonists API Product Portfolio
  168. 4.28.5 Clearsynth Labs Recent Developments
  169. 4.29 Camus Pharma
  170. 4.29.1 Camus Pharma Company Information
  171. 4.29.2 Camus Pharma Business Overview
  172. 4.29.3 Camus Pharma Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  173. 4.29.4 Camus Pharma Neurokinin Receptor Antagonists API Product Portfolio
  174. 4.29.5 Camus Pharma Recent Developments
  175. 4.30 Andenex
  176. 4.30.1 Andenex Company Information
  177. 4.30.2 Andenex Business Overview
  178. 4.30.3 Andenex Neurokinin Receptor Antagonists API Sales, Revenue and Gross Margin (2021-2026)
  179. 4.30.4 Andenex Neurokinin Receptor Antagonists API Product Portfolio
  180. 4.30.5 Andenex Recent Developments
5 Global Neurokinin Receptor Antagonists API Market Scenario by Region
  1. 5.1 Global Neurokinin Receptor Antagonists API Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Neurokinin Receptor Antagonists API Sales by Region: 2021-2032
  3. 5.2.1 Global Neurokinin Receptor Antagonists API Sales by Region: 2021-2026
  4. 5.2.2 Global Neurokinin Receptor Antagonists API Sales by Region: 2027-2032
  5. 5.3 Global Neurokinin Receptor Antagonists API Revenue by Region: 2021-2032
  6. 5.3.1 Global Neurokinin Receptor Antagonists API Revenue by Region: 2021-2026
  7. 5.3.2 Global Neurokinin Receptor Antagonists API Revenue by Region: 2027-2032
  8. 5.4 North America Neurokinin Receptor Antagonists API Market Facts & Figures by Country
  9. 5.4.1 North America Neurokinin Receptor Antagonists API Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Neurokinin Receptor Antagonists API Sales by Country (2021-2032)
  11. 5.4.3 North America Neurokinin Receptor Antagonists API Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Neurokinin Receptor Antagonists API Market Facts & Figures by Country
  16. 5.5.1 Europe Neurokinin Receptor Antagonists API Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Neurokinin Receptor Antagonists API Sales by Country (2021-2032)
  18. 5.5.3 Europe Neurokinin Receptor Antagonists API Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Neurokinin Receptor Antagonists API Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Neurokinin Receptor Antagonists API Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Neurokinin Receptor Antagonists API Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Neurokinin Receptor Antagonists API Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Neurokinin Receptor Antagonists API Market Facts & Figures by Country
  41. 5.7.1 South America Neurokinin Receptor Antagonists API Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Neurokinin Receptor Antagonists API Sales by Country (2021-2032)
  43. 5.7.3 South America Neurokinin Receptor Antagonists API Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Neurokinin Receptor Antagonists API Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Neurokinin Receptor Antagonists API Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Neurokinin Receptor Antagonists API Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Neurokinin Receptor Antagonists API Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Neurokinin Receptor Antagonists API Sales by Type (2021-2032)
  2. 6.1.1 Global Neurokinin Receptor Antagonists API Sales by Type (2021-2032) & (Tons)
  3. 6.1.2 Global Neurokinin Receptor Antagonists API Sales Market Share by Type (2021-2032)
  4. 6.2 Global Neurokinin Receptor Antagonists API Revenue by Type (2021-2032)
  5. 6.2.1 Global Neurokinin Receptor Antagonists API Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Neurokinin Receptor Antagonists API Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Neurokinin Receptor Antagonists API Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Neurokinin Receptor Antagonists API Sales by Application (2021-2032)
  2. 7.1.1 Global Neurokinin Receptor Antagonists API Sales by Application (2021-2032) & (Tons)
  3. 7.1.2 Global Neurokinin Receptor Antagonists API Sales Market Share by Application (2021-2032)
  4. 7.2 Global Neurokinin Receptor Antagonists API Revenue by Application (2021-2032)
  5. 7.2.1 Global Neurokinin Receptor Antagonists API Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Neurokinin Receptor Antagonists API Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Neurokinin Receptor Antagonists API Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Neurokinin Receptor Antagonists API Value Chain Analysis
  2. 8.1.1 Neurokinin Receptor Antagonists API Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Neurokinin Receptor Antagonists API Production Mode & Process
  5. 8.2 Neurokinin Receptor Antagonists API Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Neurokinin Receptor Antagonists API Distributors
  8. 8.2.3 Neurokinin Receptor Antagonists API Customers
9 Global Neurokinin Receptor Antagonists API Analyzing Market Dynamics
  1. 9.1 Neurokinin Receptor Antagonists API Industry Trends
  2. 9.2 Neurokinin Receptor Antagonists API Industry Drivers
  3. 9.3 Neurokinin Receptor Antagonists API Industry Opportunities and Challenges
  4. 9.4 Neurokinin Receptor Antagonists API Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst